Lupin launches novel fixed-dose triple drug combination Difizma DPI to treat inadequately controlled asthma

Lupin has launched a novel Fixed-Dose triple drug Combination (FDC) of indacaterol, lycopyrronium and mometasone for managing inadequately controlled asthma amongst patients. The company has launched the product under the brand name Difizma in India, Lupin said in a statement.

Further, according to the statement, Lupin is the first company in India to offer this novel FDC Dry Powder Inhalation (DPI) product combining indacaterol, a long-acting beta-agonist, glycopyrronium, a long-acting muscarinic receptor antagonist, and mometasone furoate, an inhaled corticosteroid.

Difizma is the only FDC that has been approved by the Drug Controller General of India (DCGI) for the treatment of inadequately controlled asthma. It will help in the management of inadequately controlled asthma by improving lung function, providing better symptom control and reducing exacerbations. The drug will be available in one strength with a fixed dose to be taken once daily, the statement added.

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05 per cent. Out of this, approximately 30 lakh patients can be classified under “inadequately controlled.” These are the patients who have uncontrolled symptoms and higher chances of exacerbations which may lead to hospitalisation contributing to higher DALYs in most patients, the statement concluded.